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TRIM5 is a RING domain E3 ubiquitin ligase with
potent antiretroviral function. TRIM5 assembles into
a hexagonal lattice on retroviral capsids, causing
envelopment of the infectious core. Concomitantly,
TRIM5 initiates innate immune signaling and orches-
trates disassembly of the viral particle, yet how these
antiviral responses are regulated by capsid recogni-
tion is unclear. We show that hexagonal assembly
triggers N-terminal polyubiquitination of TRIM5 that
collectively drives antiviral responses. In uninfected
cells, N-terminal monoubiquitination triggers non-
productive TRIM5 turnover. Upon TRIM5 assembly
on virus, a trivalent RING arrangement allows elonga-
tion of N-terminally anchored K63-linked ubiquitin
chains (N-K63-Ub). N-K63-Ub drives TRIM5 innate
immune stimulation and proteasomal degradation.
Inducing ubiquitination before TRIM5 assembly trig-
gers premature degradation and ablates antiviral
restriction. Conversely, driving N-K63 ubiquitination
after TRIM5 assembly enhances innate immune
signaling. Thus, the hexagonal geometry of TRIM5’s
antiviral lattice converts a capsid-binding protein
into a multifunctional antiviral platform.
INTRODUCTION
TRIM proteins, identified by their N-terminal tripartite motif
(TRIM; one RING domain, one or two B-Box domains, and a
coiled-coil [CC]) constitute the largest family of RING E3 ubiq-
uitin (Ub) ligases in mammals (Han et al., 2011). Many TRIMs
have key immune functions, exemplified by TRIM5, which de-
tects and inhibits retroviruses like HIV-1 (Stremlau et al.,
2004). TRIM5 self-assembles into hexagonal sheets that
‘‘cage’’ retroviral capsids (Ganser-Pornillos et al., 2011; Li
et al., 2016). There are two levels of TRIM5 self-association.
First, TRIM5 forms antiparallel homodimers via the CC, with
the RING and B-Box domains of paired molecules held apart
by 170 A˚ (Goldstone et al., 2014; Sanchez et al., 2014; Wag-Cell Host & Microbe 24, 1–15, Decem
This is an open access article under the CC BY-Nner et al., 2016). Second, each B-Box2 domain forms homo-
trimers, meaning one TRIM5 dimer forms an edge of the hexa-
gon subunit of the lattice (Figure S6A) (Ganser-Pornillos et al.,
2011; Goldstone et al., 2014; Li et al., 2016). TRIM5 oligomeri-
zation is critical for antiviral activity because the C-terminal
PRYSPRY domain, the region of TRIM5 that binds retroviral
capsid, has low affinity for capsid, which is enhanced through
avidity (Li and Sodroski, 2008; Li et al., 2016). Higher-order
structures formed by TRIM5 are sometimes referred to as cyto-
plasmic bodies (CBs) and can be provoked in the absence of
infection (Diaz-Griffero et al., 2006). However, many aspects
of these structures remain poorly understood; for instance,
the purpose of localizing three RING domains at each three-
fold vertex of the lattice. One theory is that this promotes their
dimerization and Ub ligase activity (Sanchez et al., 2016; Yu-
dina et al., 2015), but this does not explain the symmetry
mismatch. Whether this mismatch is simply a compromise of
virus binding, or serves some specific purpose, is currently
unclear.
There are two additional outcomes of TRIM5 viral recognition:
the generation of an antiviral state (Pertel et al., 2011) and virus
destruction by proteasome recruitment (Kutluay et al., 2013;
Wu et al., 2006). The latter phenomenon occurs soon after the vi-
rus enters the cytoplasm, before viral DNA (vDNA) is transcribed
(Stremlau et al., 2004). Both of these processes involve Ub
(Campbell et al., 2015; Fletcher et al., 2015; Pertel et al., 2011),
whereas mounting evidence suggests that Ub is not required
for viral caging and restriction. For example, strong inhibition of
viral infection is maintained by RING-less TRIM5 deletion mu-
tants (Diaz-Griffero et al., 2006) and in cells depleted of TRIM5’s
cognate E2 enzymes where TRIM5 autoubiquitination is
impaired (Campbell et al., 2015; Fletcher et al., 2015). One pos-
sibility is that ubiquitination occurs upon virus recognition, which
triggers downstream effector function. The question of how
TRIM5 immune stimulation is activated upon recognition of an
incoming retrovirus remains unresolved.
Here we show that TRIM5 builds a K63-Ub chain from its own
N terminus following self-assembly. A dynamic trimer of RING
domains is required to generate this modification. K63-Ub trig-
gers both immune signaling and degradation by proteasomes.
Our data suggest that the specific hexagonal geometry of the
TRIM5 lattice serves not only to enable virus binding but also
to coordinate immune signaling with pathogen recognition.ber 12, 2018 Crown Copyright ª 2018 Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Ubiquitination Is Redundant for Overall Viral Restriction
(A) B-MLV reverse transcribes its genome and integrates into the host. N-MLV recruits TRIM5, is disassembled, and cannot reverse transcribe. TRIM5 stimulates
intracellular signaling and transcriptional upregulation of antiviral genes. The timing of Ub during restriction is contested.
(B) Structure of the rhesus macaque TRIM5 RING dimer in complex with Ube2N (2N) (PDB: 4TKP).
(C and D) In vitro ubiquitination experiments between TRIM5 RING-B-Box (RB) mutants and Ube2W (C), Ube2N/Ube2V2 (2N/V2) (C and D) or both Ube2W and
2N/V2 (C and D), detecting TRIM5 or Ub.
(E and F) CrFK cells expressing vector or full-length TRIM5 mutants (bearing C-terminal hemagglutinin [HA] tags), infected with N-MLV- or B-MLV-GFP vectors.
Percentage infection quantified by flow cytometry (E and F). Boiled virus served as a negative control (E).
(G) Representative confocal fluorescence images of CrFK cells from (E) and (F), detecting HA tag or DNA.
(H) Model. The RING domain determines the morphology and restriction potency, but not the formation, of TRIM5 assemblies.
All experiments representative of at least triplicates. In (E) and (F), error bars represent SD; values are means ± SD.
Please cite this article in press as: Fletcher et al., Trivalent RING Assembly on Retroviral Capsids Activates TRIM5 Ubiquitination and Innate Immune
Signaling, Cell Host & Microbe (2018), https://doi.org/10.1016/j.chom.2018.10.007RESULTS
We began by comprehensively perturbing TRIM5 E3 ligase func-
tion, as conflicting data regarding the role of Ub in TRIM5 restric-
tion activity have emerged (Campbell et al., 2015; Fletcher et al.,2 Cell Host & Microbe 24, 1–15, December 12, 20182015; Pertel et al., 2011; Roa et al., 2012; Wu et al., 2006; Yudina
et al., 2015) (Figure 1A). We introduced structure-guided muta-
tions at three positions in the human TRIM5RING dimer interface
(N70A, V73A, I76R) and three positions at the RING-E2 enzyme
interface (E11R, L19R, V57R) (Figure 1B). Wemade recombinant
Please cite this article in press as: Fletcher et al., Trivalent RING Assembly on Retroviral Capsids Activates TRIM5 Ubiquitination and Innate Immune
Signaling, Cell Host & Microbe (2018), https://doi.org/10.1016/j.chom.2018.10.007human TRIM5 proteins comprising the RING and B-Box2 do-
mains (RBs). In solution, RB was in dynamic monomer-dimer
equilibrium; dimer interface mutants were more monomeric (Fig-
ure S1A). We tested each RING mutants’ ubiquitination activity
in vitro with cognate E2s Ube2W (2W) and Ube2N/Ube2V2
(2N/V2), which build anchored K63-polyUb chains (K63-Ub) on
TRIM5 (Fletcher et al., 2015). Wild-type (WT) TRIM5 RBs pro-
duced unanchored Ub chains of heterogeneous lengths with
2N/V2 alone (Figure 1C, lane 6), and a high molecular weight
(Mw), more homogeneous length anchored chain with 2N/V2
and 2W (Figure 1C, lane 8). Monoubiquitinated RB was gener-
ated with 2W alone (Figure 1C, lane 7). The RING dimer mutants
were all strongly impaired in anchored chain elongation and
reduced for monoubiquitin (monoUb). I76R and V73A, but not
N70A, were also impaired for free chain synthesis, suggesting
that mechanisms of chain extension from free or anchored Ub
are distinct (Figure 1C). Each E2 interface mutant was severely
disabled in the synthesis of both kinds of polyUb (Figure 1D),
and E11R and V57Rwere also reduced formonoUb (Figure S1B).
Overall, anchored K63-Ub synthesis was very sensitive to muta-
tion of either the RING dimer or E2 interfaces.
To determine how these alterations affect antiviral function, we
expressed full-length human TRIM5 mutants in permissive feline
CrFK cells and infected them with TRIM5-sensitive N-tropic
murine leukemia virus (N-MLV) or TRIM5-insensitive B-MLV
retroviral vectors carrying a GFP reporter gene. The E2 interface
mutants E11R, L19R, and V57Rmaintained WT levels of antiviral
activity (Figure 1E) despite not producing any polyUb in vitro. The
RING dimer interface mutants suffered a partial loss in antiviral
activity but retained the ability to restrict N-MLV infection by
10-fold (Figures 1E and 1F), despite N70A retaining free chain
synthesis activity in vitro where V73A had lost it (Figure 1B).
Therefore, the partial loss of restriction activity by the RING
dimer interface mutants is more consistent with a structural
contribution made by the RING dimer to the restrictive lattice
(Li et al., 2016; Wagner et al., 2016). To test this, we deleted
the RING domain entirely and assessed its restriction activity in
parallel. As expected, loss of the RING domain only caused a
partial loss of restriction; 10-fold inhibition of infection remained
(Figure 1E). Conversely, the B-Box self-association mutant
R119E was completely unable to restrict infection (Figure 1E)
(Diaz-Griffero et al., 2007), confirming that higher-order assem-
bly, but not ubiquitination, is required for TRIM5’s restriction
activity.
TRIM5 self-assembly is shown by the formation of dynamic
puncta called CBs. MG132 slows TRIM5 degradation and aug-
ments CB size (Figure 1G) (Campbell et al., 2008). TRIM5
B-Box mutant R119E does not self-associate (Wagner et al.,
2016) or form CBs (Diaz-Griffero et al., 2007) even after MG132
treatment (Figure 1G), consistent with its failure to restrict infec-
tion (Figure 1E). However, each RING mutant formed subcellular
structures, even in the absence of MG132, consistent with effec-
tive self-association and potent antiviral activity (Figure 1G).
Notably, although mutant E11R formed regular CB like WT (Fig-
ure 1G), mutants L19R and V57R formed larger structures (Fig-
ures 1G and 1H), which we predict are derived from CBs that
have grown due to impaired disassembly (see below). In
contrast, the DRING and dimer mutants formed hollow spheres
(Figures 1G and 1H), consistent with the RING dimer making astructural contribution to the restrictive lattice (Figure 1E).
Thus, interfering with TRIM5 ubiquitination affects CB growth
and persistence, suggesting ubiquitination plays a crucial role
in disassembly of the TRIM5 platform.
TRIM5 has a proteasome-dependent short half-life in cells
(Diaz-Griffero et al., 2006). Cycloheximide chase experiments re-
vealed that each of the six RINGmutants failed to turn over effec-
tively (Figures 2A and 2B; compare with WT in the presence of
MG132; Figure S2A), agreeing with exaggerated assembly phe-
notypes (Figure 1). Turnover of E11R was reduced but not abol-
ished, consistent with the WT-like CB that this mutant formed
(Figure 1G). TRIM5 turnover was also abolished if self-associa-
tion was prevented by mutation R119E (Figure S2B) (Li and So-
droski, 2008), suggesting TRIM5 self-association is required to
bring RING domains together, recruit E2s, and initiate Ub-
dependent turnover.
TRIM5-mediated virus disassembly occurs soon after virus en-
try and causes an inhibition of vDNA synthesis (Kutluay et al.,
2013; Stremlau et al., 2004), which thus serves as a quantitative
assay for virus disassembly (Roa et al., 2012). Proteasome inhibi-
tion, in addition to preventing TRIM5 turnover (Figure S2A) (Diaz-
Griffero et al., 2006; Rold and Aiken, 2008), selectively restores
vDNA synthesis but not infection (Wu et al., 2006). We infected
CrFK expressing empty vector, WT, E11R, L19R, V57R, I76R,
R119E, or DRING TRIM5, with N- or B-MLV and measured the
level of vDNA at 6 hr post-infection. Vector and WT TRIM5 ex-
pressing cells were additionally treated with MG132. As ex-
pected, WT TRIM5 potently reduced the levels of vDNA;
MG132 treatment, or RING deletion, restored vDNA synthesis
(Figure 2C), but not viral infection (Figure 1E). R119E was
completely inactive, as expected. RING mutants L19R, V57R,
and I76R were also unable to inhibit vDNA synthesis, consistent
with a failure to recruit proteasomes via Ub chain formation.
The E11R mutant retained weak restriction of vDNA synthesis
consistent with reduced, but not abolished, turnover
(Figure 2A). To confirm the pathway was conserved in human
cells, we also deleted TRIM5 by CRISPR/Cas9 in TE671 cells,
then reconstituted with WT, L19R, or R119E mutant TRIM5. As
in CrFK, only WT TRIM5 conferred a potent block to N-MLV
vDNA synthesis (Figures 2D and S2C), while both WT and L19R
TRIM5 conferred potent restriction of viral infection (Figure 2E).
Therefore, affecting TRIM5 ubiquitination in both feline and hu-
man cells impairs virus disassembly but not viral restriction.
To correlate ubiquitination specificity in vitro and in cells, we
probed TRIM5 assemblies for Ub. Using a linkage-specific anti-
body, we found that WT CBs were rich in K63-Ub; 96% of CBs
were K63-Ub positive (Figure 2F). In contrast, 16%, 2%, and
5% of the assemblies formed by RING mutants E11R, L19R,
and I76R, respectively, were labeled with K63-Ub (Figure 2F).
Thus, RINGmutants with ubiquitination defects in vitro (Figure 1)
are unable to turn over, inhibit vDNA synthesis, or catalyze K63-
Ub formation in cells. These data are consistent with a model in
which TRIM5 undergoes self-association, autoubiquitinates, re-
cruits proteasomes, and disassembles viral cores before signif-
icant vDNA synthesis occurs. However, this model assumes that
TRIM5 autoubiquitination drives its own destruction at the pro-
teasome, with premature virus disassembly (and degradation)
an antiviral by-product. To understand whether TRIM5 RING-
dependent K63-Ub synthesis can drive proteasome-dependentCell Host & Microbe 24, 1–15, December 12, 2018 3
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Figure 2. Ubiquitination Drives TRIM5 Turnover and Virus Destruction
(A and B) Left: cycloheximide (CHX) chase experiments of CrFK cells expressing full-length TRIM5 E2 interface mutants (A) or TRIM5 RING dimer mutants (B),
bearing C-terminal HA tags (A and B). Immunoblots detecting HA tag or b-actin. Right: densitometry of immunoblots shown.
(C and D) CrFK cells (C) or TE671 cells transduced with Cas9 and TRIM5-specific single guide RNA (D) and expressing empty vector or full-length TRIM5mutants
(bearing C-terminal HA tags), infected with N-MLV- or B-MLV-GFP vectors, viral DNA copies quantified by GFP TaqMan qPCR. In (C), vector or WT TRIM5 cells
were also treated with 10 mM MG132. Boiled virus served as a control for plasmid contamination.
(E) TE671 cells from (D) infected with N-MLV-GFP or B-MLV-GFP vectors, percentage infection quantified by flow cytometry.
(F) Representative confocal fluorescence images of CrFK cells expressing full-length TRIM5 mutants (bearing C-terminal HA tags), detecting HA tag, K63-Ub, or
DNA. Cells containing K63-Ub-positive CBs were counted and expressed as percentage of total cells counted.
All data are representative of at least two replicates. (C–E) Error bars represent SD. In (F), n = number of cells counted in the experiment shown.
Please cite this article in press as: Fletcher et al., Trivalent RING Assembly on Retroviral Capsids Activates TRIM5 Ubiquitination and Innate Immune
Signaling, Cell Host & Microbe (2018), https://doi.org/10.1016/j.chom.2018.10.007degradation, we required deeper understanding of TRIM5 ubiq-
uitination in cells.
TRIM5 ubiquitination also drives innate immune signaling, but
how Ub signaling assimilates with restriction is poorly under-
stood. To investigate this, we first measured innate immune
signaling pathways during restriction of N-MLV infection by
endogenous TRIM5 in THP-1 cells. We observed transcriptional
upregulation of cytokines IL6, IL1B, IFNB1, and TNFA, and en-
zymes IFIT1, NLRP3, PTGS2, and SOD2, in response to N-,
but not B-MLV (Figure 3A). PTGS2 and SOD2 were previously
found in a screen for TRIM5-regulated genes in these cells (Pertel
et al., 2011). The response was TRIM5 dependent (Figure 3B);
TRIM5 depletion by small hairpin RNA was confirmed by rescue
of restricted N-MLV infection (Figure 3C). To determine whether
immune gene transcription is induced by TRIM5 activation of the
NF-kB pathway, we monitored canonical NF-kB signaling by4 Cell Host & Microbe 24, 1–15, December 12, 2018immunoblot and immunofluorescence microscopy during viral
infection. This approach revealed a striking phosphorylation of
IkBa at serines 32/36 (Figure 3D), and relocation of NF-kB sub-
unit p65 from the cytoplasm to the nucleus (Figure 3E) upon chal-
lenge with N-, but not B-MLV. These data confirm that TRIM5
performs pattern recognition during retroviral restriction, result-
ing in activation of NF-kB and immune gene induction.
Transient TRIM5 overexpression is sufficient to activate NF-kB
signaling in the absence of infection and can be detected in lucif-
erase reporter assays (Pertel et al., 2011). We confirmed that
such NF-kB signaling also results in cytokine transcription, by
measuring upregulated expression of IL6 and PTGS2 (Figures
3F and 3G). We hypothesized that enforced TRIM5 assembly
in the absence of a viral template drives this phenomenon.
B-Box mutant R119E was unable to stimulate NF-kB (Fig-
ure 3H) and was significantly less decorated by Ub (Figure 3I),
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Figure 3. TRIM5 Cytoplasmic Bodies Are Signaling Platforms
(A and B) (A) Differentiated THP-1 cells infected with N- or B-MLV vector, or media alone, and mRNA fold inductions relative to media were quantified (DDCt) by
qPCR using ACTB as an uninduced control. In (B), THP-1 expressed control (shScr) or TRIM5-specific (shTRIM5) small hairpin RNA (shRNA).
(C) THP-1 from (B) were infected with N- or B-MLV-GFP and percentage infection quantified by flow cytometry.
(D) Differentiated THP-1 cells infected with N- or B-MLV, or 10 ng/mL TNFa, for times indicated. Immunoblots detecting phospho-IkBa, IkBa, and b-actin.
(E) Representative confocal fluorescence images of differentiated THP-1 cells, infected with N- or B-MLV for the times indicated, detecting p65 or DNA.
(F and G) TRIM5, PTGS2 (F), and IL6 (G) expression relative to ACTB in 293T following transfection with WT or E11R (G) TRIM5.
(H) NF-kB-Luc activation in 293T by WT or R119E TRIM5.
(I) Immunoblot of WT or R119E TRIM5-His pull-downs (PDs) from 293T cells, detecting Ub in PD fraction and TRIM5 or b-actin in input fraction.
(J) Representative confocal fluorescence images of 293T transfected with increasing doses of TRIM5 plasmid (bearing C-terminal HA tag), NF-kB-FLuc, and
RLuc, detecting HA tag or DNA. Cells classified as containing diffuse TRIM5, CBs, aggregated TRIM5 (aggregates), or aggregates andCBs. Cells counted in eight
fields of view, and different cell classes represented as parts of a whole.
(K) NF-kB-FLuc activation in cells from (J), plotted against the number of cells at each plasmid dose containing either CB or aggregates.
(L) NF-kB-Luc activation in 293T by WT, E11R, L19R, or I76R TRIM5.
All data are representative of at least two replicates. All data are mean values; error bars represent SD. See also Figure S3.
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Figure 4. TRIM5 CBs Harbor N-Terminal Ub
(A) Coomassie gel of in vitro reaction between 2W and TRIM5 RB. Dotted box indicates region excised for LC-MS/MS.
(B) Tandem mass spectrometry spectra of the N-terminal diGly-modified N-terminal peptide identified in (A).
(C) Immunoblots of in vitro ubiquitination reactions between UbRB, 2W, and 2N/V2, detecting TRIM5 (top) and Ub (bottom). Circle indicates free RB protein
co-purified with UbRB; asterisk indicates enzymatically synthesized UbRB.
(legend continued on next page)
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activation, autoubiquitination, and signaling. To further explore
the correlation, we measured NF-kB activation and CB fre-
quency upon titration of transfected TRIM5 plasmid in 293T
cells. At low TRIM5 levels, the protein formed numerous micro-
meter-sizedCBs per cell and bothCB formation andNF-kB stim-
ulation increased with plasmid dose (Figures 3J, 3K, S3A, and
S3B). At plasmid doses above 5 ng, NF-kB stimulation declined,
despite a steady increase in the number of CB-containing cells.
However, the reduction in NF-kB signaling was accompanied by
a rising frequency of TRIM5 aggregates (Figures 3J, 3K, S3A,
and S3B), which closely resembled the aggregates formed by
E2 binding mutants L19R and V57R (Figure 1G). NF-kB output
was greatest when CB numbers were high and aggregate
numbers low (Figure 3K). We hypothesize that the discrete
CBs, which localize around virus during restriction (Campbell
et al., 2008), contain enzymatically active TRIM5. In contrast,
the large aggregates contain inactive TRIM5 and repress
signaling through protein misfolding or sequestration. As
TRIM5 expression increases and drives self-assembly, first
functional CBs form and then larger non-functional aggregates
accumulate, explaining the bell-shaped response curve. We
observed equivalent bell-shaped NF-kB stimulation profiles by
TRIM1, TRIM32, and TRIM38 (Figure S3C), whereas IKK2 stimu-
lation of NF-kB was not self-limiting and increased exponentially
with dose (Figure S3C). TRIM5 RING-E2 interfacemutants E11R,
L19R, and I76R ( restriction proficient but ubiquitination deficient
in cells and in vitro; Figure 1) were defective for NF-kB activation
(Figures 3G and 3L), despite forming discrete cytoplasmic
puncta (Figure S3D). Thus, these mutants separate ubiquitina-
tion from antiviral activity, and antiviral activity from innate
immune signaling. TRIM5 self-association drives inflammatory
polyUb synthesis, suggesting CBs and the restrictive lattice
are signaling platforms.
To investigate which Ub species form within inflammatory
CBs, we first sought evidence for monoUb. Depletion of 2N/V2
in cells reveals a 2W-dependent TRIM5 species bearing a single
Ub (Fletcher et al., 2015), suggesting a single site of Ub conjuga-
tion. 2W has a specialized active site and flexible C-terminal re-
gion, which collectively favor ubiquitination of N-terminal over
lysine amines (Tatham et al., 2013; Vittal et al., 2015). However,
mass spectrometry has not detected authentic N-terminal ubiq-
uitinated peptides in cells, making the existence of this modifica-
tion and its functional significance difficult to study. To determine
whether TRIM5 is labeled at its N terminus in CBs, we therefore
adopted a combined in vitro and cellular approach. We first
confirmed that 2W targets the TRIM5 N terminus in vitro. The
RB proteins we used had non-acetylated N termini and seven
available lysine residues. Upon incubation with 2W, we observed
robust auto-monoubiquitination, shown by depletion of the RB
band and appearance of a band corresponding with monoUb-(D) ELISA of sera from four mice, one naive and three immunized with recombin
(E) Immunoprecipitation (IP) of TRIM5-HA from TE671 expressing control (s
(T5 N-monoUb) or anti-TRIM21 RING-B-Box (T21 RB) sera, detecting HA tag in
(F and G) Representative confocal fluorescence images of TE671 expressing TR
TRIM5DRING or TRIM5 7KR (C-terminal HA tag), detecting N-monoUb (F), K63-
All data are representative of at least duplicates. **Unpaired t test, p < 0.01. ***U
represent SD. In (F), n = 2, 100 cells scored per condition per replicate. In (G),RB (Figure 4A). Discrete higher-Mw bands were also observed
in Coomassie gels (Figure 4A), suggesting monoubiquitination
of 2W also occurs (Tatham et al., 2013), as well as secondary
monoubiquitination on RB lysine residues once the N terminus
has been conjugated (Fletcher et al., 2015; Vittal et al., 2015),
as suggested by western blots for TRIM5 (Figure S1B). However,
mass spectrometric analysis of the excised monoUb-RB band
confirmed that the predominant Ub conjugation had occurred
exclusively at the RBN terminus; only N-terminal diGly-modified,
but not lysine-modified diGly, peptides were detected (Fig-
ure 4B). To determine whether N-terminal monoUb (N-monoUb)
is able to prime anchored K63-Ub synthesis by TRIM5, wemade
a linear UbRB fusion protein by genetically fusing Ub to the
TRIM5 RB N terminus. In the presence of 2N/V2, recombinant
UbRB became robustly labeled with anchored polyUb (Fig-
ure 4C). Importantly, this activity was now independent of 2W
(Figure 4C, compare lanes 3 and 7). Thus, N-monoUb is a primer
for TRIM5-anchored K63-Ub (N-K63-Ub).
Previously, we detected acetylated TRIM5 N termini by mass
spectrometry, following non-denaturing purification of overex-
pressed TRIM5 in cells (Fletcher et al., 2015). We re-examined
this observation by denaturing cells with guanidine before affinity
purification of ectopically expressed TRIM5. Trypsin digests of
captured protein were assessed by liquid chromatography-tan-
dem mass spectrometry (LC-MS/MS). While we were unable to
identify di-Gly-modified N-terminal peptides, as expected, this
approach revealed both acetylated and non-acetylated (deme-
thionylated) N termini, suggesting that the TRIM5 N terminus in
cells is not constitutively acetylated (Figure S4A). Knowing 2W
can modify non-acetylated TRIM5 N termini (Figures 4A and
4B), we generated N-monoUb-specific antisera by immunizing
mice with recombinant UbRB. From here on, we used linear
UbRB proteins bearing Gly-Ala substitution at the two final resi-
dues of Ub, which prevented deubiquitination in bacteria
(Ub(GA)RB) (Figure S4B). Antisera from several mice were highly
specific to Ub(GA)RB and poorly recognized either Ub or un-
modified RB by ELISA (Figure 4D). To ensure specificity, we
depleted RB-reactive antibodies from the serum by incubation
on RB-coated plates. The resultant antiserum efficiently immu-
noprecipitated ectopic TRIM5 from control cells, but not from
2W-depleted cells (Figures 4E and S1C), suggesting that
TRIM5 is labeled with N-monoUb in cells. Conversely, immuno-
precipitation of full-length ectopic Ub(GA)TRIM5 was insensitive
to 2W depletion (Figures S1C and S4C), demonstrating that ge-
netic fusion of N-monoUb to TRIM5 obviates 2W dependence in
cells as it had in vitro (Figure 4C).
We next used our specific antibodies to determine if
N-monoUb occurs within TRIM5 CB. We stably expressed WT
or mutant TRIM5 in TE671 cells treated with MG132 to enhance
CB visibility (Campbell et al., 2008; Wu et al., 2006). CBs formed
by WT TRIM5 were robustly detected by the anti-N-monoUbant Ub(GA)RB, measuring binding to recombinant Ub, RB, or Ub(GA)RB.
hScr) or 2W-specific (sh2W) shRNA, using anti-N-terminal monoubiquitin
IP or input fractions.
IM5 or Ub(GA)TRIM5 (C-terminal HA tag), and shScr or sh2W; or expressing
Ub (G), HA tag, and DNA. Scale bar, 10 mm.
npaired t test, p < 0.001. n.s., not significant; n.d., not determined. Error bars
n = 2, 40–60 cells scored per condition per replicate.
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Figure 5. N-Terminal Ub Promotes TRIM5 Immune Signaling, Chain Anchoring, and Proteasomal Degradation
(A) Representative confocal fluorescence images of 293T transfected with TRIM5-HA or Ub(GA)TRIM5-HA, NF-kB-Luc, and RLuc, detecting HA tag or DNA, and
frequency of CB-containing cells quantified.
(B) Top: NF-kB-Luc activation in cells from (A). Bottom: immunoblot detecting HA tag and b-actin.
(C) 2N/V2Ub discharge experiments with Ube2N(K92R). Left: reactions assessed by immunoblot detecting 2N (top) or TRIM5 (bottom two panels). Asterisk
indicates contaminant protein. Right: densitometry of immunoblot shown.
(D) LC-MS/MS analysis of 293T-expressed Ub(GA)TRIM5-His identifies four sites of Ub conjugation in N-monoUb, as inferred by modification of Lys with diGly
(GG). Ubiquitinated peptides shown in blue. Peptide confidence in parentheses.
(E) Immunoblot of in vitro reactions between TRIM5 RB, Ub(GA)RB, or Ub(K63R,GA)RB and 2N/V2, detecting TRIM5 (top) or Ub (bottom).
(F and G) Top: NF-kB-FLuc activation in 293T by TRIM5 (F) or GFP (G) constructs indicated. Bottom: immunoblot detecting HA tag and b-actin.
(H) Immunoblot of in vitro reactions between TRIM5 Ub(GA)RB or Ub(GA)RB(E11R) and 2N/V2, detecting TRIM5.
(I) Top: NF-kB-Luc activation in 293T by constructs indicated. Bottom: immunoblot detecting the HA tag and b-actin.
(J) Immunoblot of in vitro reactions between TRIM5 Ub(GA)RB, first conjugated with N-K63-Ub by 2N/V2, and proteasomes, incubated for 1–15 hr, detecting
TRIM5.
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certain TRIM5 lysine residues in vitrowhen the TRIM5N terminus
was acetylated (Fletcher et al., 2015). However, CBs formed by
the TRIM5 7KR mutant, containing Lys-Arg substitutions at the
seven positions targeted by 2W and thus refractory to modifica-
tion at these positions, were also detected by the anti-
N-monoUb serum (Figure 4F). Interestingly, 2W depletion
increased the frequency of large TRIM5 aggregates that
bore hallmarks of aggresomes; mean diameter 9.6 ± 2.2 mm
(n = 66), perinuclear and vimentin caged (Figures S1C and
S4D) (Johnston et al., 1998). Critically, these TRIM5 aggresomes
were invisible to the anti-N-monoUb serum (Figure 4F). Bypass-
ing 2W by genetically installing N-monoUb (Ub(GA)TRIM5) led to
N-monoUb-rich CBs regardless of 2W expression (Figure 4F),
supporting the model that 2W catalyzes TRIM5 N-monoUb
in cells. As expected, spherical assemblies formed by
TRIM5DRING were invisible to the antiserum (Figure 4F). WT
CBs were also labeled with K63-Ub (Figure 4G), which, like
N-monoUb, was RING dependent, confirming the ectopic
TRIM5 was responsible for ubiquitination (Figure 4G). Impor-
tantly, 2W depletion reduced K63-Ub detection to 24% of
CBs, suggesting that the majority of the K63-Ub signal comes
from Ub chains anchored to TRIM5 by 2W and not unanchored
K63-Ub chains (Figure 4G). CBs formed by TRIM5 7KR were
also robustly labeled with K63-Ub (Figure 4G), indicating that
the 2W-dependent K63-Ub signal was lysine independent.
Together, these data suggest that inflammatory CBs are sites
of N-K63-Ub synthesis.
We next asked whether N-K63-Ub chains contribute to NF-kB
activation. Given that TRIM5 CB frequency was proportional to
NF-kB activation at low plasmid dose (Figure 3), we first
compared CB formation by full-length WT or Ub(GA)TRIM5 at
low-dose expression in 293T cells. No MG132 was used in these
transient experiments. Interestingly, although Ub(GA)TRIM5
could undergo self-assembly, its CBs were much less frequent
than WT CBs (Figure 5A), suggesting N-monoUb disfavors CB
stability. In spite of this, and equivalent protein expression
compared with WT, Ub(GA)TRIM5 was substantially more effec-
tive at stimulating NF-kB (Figure 5B). N-monoUb did not affect
the RING monomer-dimer equilibrium (Figure S5A), indicating it
had not enhanced E3 ligase activity per se. Indeed, the RB and
Ub(GA)RB proteins were equally effective at stimulating Ub
discharge by 2N (Figure 5C). However, Ub(GA)RB uniquely pro-
moted Ub discharge onto itself, despite the fact that the E3 and
E2Ub were incubated with a vast excess of free Ub and lysine
to act as Ub acceptors (E3 at 1.5 mM, Ub at 18 mM, lysine at
50 mM) (Vittal et al., 2015). Thus, N-monoUb favors anchored
over free K63-Ub synthesis, revealing a correlation between
NF-kB activation and anchored K63-Ub.
Next, we found that the N-monoUb was ubiquitinated at resi-
dues K11, K29, K48, and K63 in 293T cells (Figure 5D). In vitro,
mutation of K63 in N-monoUb abolished anchored, but not
free, polyUb synthesis by Ub(GA)TRIM5 (Figure 5E), pinpointing(K) Left: Coomassie-stained gel of reactions between Ub(GA)RB with and wit
LC-MS/MS analysis labeled a–d. X indicates the degradation product. Right: uniqu
specific peptides were detected. Representative of three experiments.
(L) Model, TRIM5 stimulates NF-kB and proteasome degradation via an N-K63-U
All data are representative of at least two replicates. Error bars represent SD. SeK63 as the sole acceptor lysine for anchored polyUb. We there-
fore mutated all N-monoUb lysines in full-length Ub(GA)TRIM5
except K63, anticipating this would license functional TRIM5
autoubiquitination (N-K63-Ub) but block signals originating
from K11, K29, and K48. Strikingly, this manipulation further
enhanced NF-kB activation by TRIM5 in 293T cells (Figure 5F),
supporting the notion that N-K63-Ub in CB is inflammatory in
nature.
The effect of N-monoUb was TRIM5 specific because non-
hydrolyzable Ub(G76V)GFP fusions did not activate NF-kB
(Figure 5G). Moreover, RINGmutants E11R, L19R, or V57R intro-
duced into Ub(K63only,GA)TRIM5, to prevent all autoubiquitina-
tion using 2N/V2 (Figure 5H) eliminated NF-kBactivation (Figures
5I and S5B). B-Box mutant R119E also abolished NF-kB activa-
tion by this construct (Figure S5B), consistent with a model
whereby N-K63-Ub extension only occurs after TRIM5 self-as-
sociation (see below). I44A, A46E, and G47E mutation of the
Ub hydrophobic patch bound by Ube2V2 (Branigan et al.,
2015) (Figure S5C) impaired anchored Ub chain extension
on Ub(GA)RB in vitro (Figure S5D) and NF-kB activation
by Ub(K63only,GA)TRIM5 in cells (Figure S5B), confirming
that Ube2V2 mediates inflammatory chain extension from
N-monoUb. We conclude that N-monoUb fusion bypasses 2W,
drives anchored N-K63-Ub synthesis, and augments the
NF-kB response.
We next sought to reconstitute TRIM5 degradation in vitro. We
assembled HMWN-K63-Ub on TRIM5 RB by incubating Ub(GA)
RB protein with 2N/V2 (Figure 5J, lane 1) before adding protea-
somes purified from TE671 cells (Figure S5E). Proteasomes effi-
ciently removed polyUb from Ub(GA)RB by 1 hr (Figure 5J,
lane 2). Longer incubations generated a low-Mw TRIM5 degra-
dation product of 14 kDa (Figure 5J, lanes 3–4). LC-MS/MS anal-
ysis of this band (Figure 5K, band b) revealed an abundance of
both Ub- and TRIM5-derived peptides (Figure 5K, right). Impor-
tantly, all N-terminal Ub peptides bore a GSHM tag, which was
present in recombinant Ub(GA)RB but not recombinant Ub (Fig-
ure 5K, bottom). This suggests that Ub(GA)RB had been proteo-
lysed within the RING domain, rather than only deubiquitinated.
Supporting this, LC-MS/MS analysis of lower-Mw gel fragments
revealed an abundance of TRIM5-derived peptides only in reac-
tions containing proteasomes (Figure 5K, bands c and d). Incu-
bation of Ub(GA)RB with proteasomes in the absence of
N-K63-Ub did not drive equivalent TRIM5 degradation (Fig-
ure S5F). These experiments suggest that N-K63-Ub also facili-
tates TRIM5 proteasomal degradation.
Assembly-dependent TRIM5 NF-kB activation suggests the
system has evolved to ensure innate immune stimulation only
occurs following recognition of incoming virus. However,
TRIM5 is capable of spontaneous self-assembly and undergoes
turnover in the absence of virus, presumably without inflamma-
tory signaling. We therefore investigated the consequences of
priming ubiquitination prior to TRIM5 assembly. Surprisingly,
stably expressed Ub(GA)TRIM5 was devoid of restriction activityhout prior Ub conjugation by 2N/V2, and proteasomes. Bands excised for
e Ub(GA)RB peptides detected. Bottom: regions (i–iii) of Ub(GA)RB fromwhich
b tag.
e also Figure S5.
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Figure 6. N-Terminal Ubiquitination before TRIM5 Assembly Causes Premature Proteasome Recruitment
(A and B) CrFK cells expressing WT or Ub(GA)TRIM5 RING mutants (A) or Ub mutants (B), infected with N-MLV- or B-MLV-GFP; percentage infection quantified
by flow cytometry.
(C) Representative confocal fluorescence images of CrFK cells expressing constructs indicated, treated with DMSO or 10 mMMG132, detecting HA tag or DNA.
(D) Number of visible CBs per cell, from (C).
(E) CrFK cells from (C) infected with N-MLV- or B-MLV-GFP, percentage infection quantified by flow cytometry.
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copies quantified by TaqMan GFP qPCR (G). In (G), cells were also treated with DMSO or 10 mM MG132. Boiled virus served as a control for plasmid
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All data are representative of at least two replicates. Error bars represent SD.
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self. The Ub fusion degradation (UFD) machinery constitutes
several E3s that recognize N-terminal Ub and direct it to the pro-
teasome (Johnson et al., 1995; Zhao and Ulrich, 2010). Given
K11, K29, and K48 of Ub(GA)TRIM5 were also ubiquitinated (Fig-
ure 5D), we reasoned that lack of restriction by Ub(GA)TRIM5
could be due to premature proteasome recruitment via the
UFD. Indeed, ablating TRIM5 autoubiquitination and protea-
some recruitment with mutants E11R or V57R (Figure 2) did
not rescue the antiviral activity of Ub(GA)TRIM5 (Figure 6A).
We observed a modest rescue in restriction by mutating K48,
but not K63, to arginine in Ub(GA)TRIM5 (Figure 6B), supporting
UFD involvement. Strikingly, however, while WT formed
numerous CBs per cell, stably expressed Ub(GA)TRIM5 formed
no visible CBs (Figures 6C and 6D), consistent with pre-assem-
bly degradation. However, Ub(GA)TRIM5 could form CBs under
MG132 treatment (Figures 6C and 6D) and, critically, MG132
also restored viral restriction activity (Figure 6E). Like WT
TRIM5 (Figure 1), restriction of infection was entirely dependent10 Cell Host & Microbe 24, 1–15, December 12, 2018on higher-order assembly, as shown by Ub(GA)TRIM5 R119E
neither forming CBs nor restricting infection in the presence of
MG132 (Figures 6C–6E). Next, we mutated all lysines, except
K63, in the N-monoUb of Ub(GA)TRIM5. We did this because
K63 is a UFD target, and the TRIM5 RING, using 2N/V2, exclu-
sively targets N-monoUb K63 (Figure 5E). Remarkably, this
manipulation also restored viral restriction to Ub(GA)TRIM5 (Fig-
ure 6F). Thus protected from the UFD pathway, Ub(K63only,GA)
TRIM5 restricted viral DNA synthesis in a proteasome inhibitor
(MG132)-sensitive way (Figure 6G) and formed WT-like CBs
that enlarged on MG132 treatment (Figure 6H), indicative of
K63-Ub-dependent proteasome recruitment. We conclude that
the UFD pathway, via non-K63 ubiquitination, precludes CB for-
mation in the absence of a virus. On recruitment of TRIM5 to viral
capsid, formation of N-K63 chains, catalyzed by TRIM5 itself,
overwhelms local UFD activity to drive innate immune signal
activation.
We next asked what property of TRIM5 assembly favored in-
flammatory N-K63-Ub synthesis, hypothesizing that the 3-fold
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gested that RING dimerization allows unanchored Ub chains to
be synthesized at the 3-fold vertex to enable antiviral activity.
To bias TRIM5 ligase activity toward free Ub chain synthesis,
we constructed and purified a recombinant tandem RING pro-
tein, connected by a two-residue linker, including sufficient
RING residues to form the ‘‘four-helix bundle’’ that allows
RING dimerization (Koliopoulos et al., 2016; Sanchez et al.,
2016; Yudina et al., 2015). Despite normalizing for RING domain
concentration, the constitutive RING dimer was significantly
more effective at generating free Ub chains than a single RING
(Figure 7A). We then substituted the tandem RING for the single
RING in full-length TRIM5 (Figure 7B). However, RING-RING-
TRIM5 was inactive for NF-kB activation in cells (Figure 7C).
Strikingly, introducing the I76R RING dimer interface mutation
into either of the fused RING domains restored activity, demon-
strating that constitutive dimerization negatively affected activity
(Figures 7B and 7C). Restored signaling was both E2 and assem-
bly dependent, as shown by the inhibitory effects of E11R
or R119E mutations, respectively (Figures 7B and 7C). Thus,
free chain synthesis in vitro is not predictive of cellular signal
activation.
Alternatively, we envisaged that a RING monomer could ubiq-
uitinate itself (Figure 7D model 1), or a RING monomer could
ubiquitinate its partner in the dimer (Figure 7D model 2). How-
ever, existing RING:E2 structures suggest 2N/V2 cannot reach
an N-monoUb attached to the same RING dimer to which the
E2 is bound (Figure S6B), disfavoring these cis models. A third
scenario is that a RING dimer conjugates Ub to the third mono-
meric RING in trans (Li et al., 2016; Wagner et al., 2016; Yudina
et al., 2015) (Figure 7D model 3). To test this, we designed a
‘‘ubiquitination rescue’’ experiment, whereby we incubated a
catalytically dead TRIM5 E3 with a catalytically active TRIM5
E3 to monitor labeling of the dead substrate in trans. To the tan-
dem RING protein, we genetically installed non-hydrolyzable Ub
at its N terminus, and a FLAG tag at the C terminus (UbRRFLAG)
(Figure 7E). Incubation of UbRRFLAG (WT) with 2N/V2 led to
TRIM5-anchored Ub chains (Figure 7F). As expected, chain
extension was Ub K63 and Ube2V2 dependent (Figure S6C).
To inactivate this E3, we introduced E11R substitutions into
both RING domains (ER). This protein remained completely un-
modified in the presence of 2N/V2 (Figure 7F). However, when
incubated with equimolar amounts of a non-FLAG-tagged
UbRR dimer (hence invisible to FLAG-specific antibodies) ER
became modified, as detected by western blot (Figure 7F). This
demonstrated that TRIM5 ubiquitination could occur in trans be-
tween a RING dimer and an adjacent N-monoUb-RING.
However, trans polyUb extension was inefficient, extending by
2–3 Ubmolecules only (Figure 7F). Surprisingly, detection of total
TRIM5 revealed that FLAG-less UbRR protein had fully extended(C) Top: NF-kB-Luc activation in 293T by constructs listed in (B). Bottom: immun
(D) Three models for Ub chain extension from N-monoUb by 2N/V2 in a three-RI
(E) Schematic of recombinant Ub(GA)RING-RING proteins purified.
(F) Immunoblots of in vitro reactions between proteins listed in (E) and 2N/V2, de
(G) Immunoblot of time course of in vitro reaction between UbRR and 2N/V2, de
(H) Schematic of a dynamic two-plus-one RING arrangement. A chain is initiate
adjacent RING dimer. RINGs exchange partners and further elongation by 2N/V2
All data are representative of at least two replicates. Error bars represent SD.
12 Cell Host & Microbe 24, 1–15, December 12, 2018its N-monoUb into a high-Mw chain (Figure 7F, lane 5). This indi-
cated that intra-dimer cis Ub chain extension had also occurred.
We repeated ubiquitination rescue experiments using unlabeled
UbRR proteins bearing an E11R mutation in one or other RING
domain (Figures 7E and 7F), revealing that mutation of RING2,
opposite monoubiquitinated RING1, completely abrogated cis
Ub chain extension. By contrast, synthesis of unanchored Ub
chains did not require cooperation between multiple RINGs (Fig-
ure 7F). Accepting the structural limitations presented by avail-
able models (Figure S6B), these data suggest that a trans
reaction between a RING dimer and a monomeric N-monoUb-
RING can initiate an N-terminal Ub chain (2–3 Ub molecules).
Ube2V2 can then coordinate the outermost Ub given the addi-
tional chain length provided (Figure S6B), and intra-dimer cis
extension preferentially occurs. Supporting this, N-K63-Ub syn-
thesis displayed two-step kinetics in a time-course experiment.
Although free Ub chain synthesis by UbRR occurred in a step-
wise fashion, whereby all intermediate chain lengths were de-
tected, only species representing an initiated N-K63-Ub, or a
fully extended N-K63-Ub, were identified. Initiated Ub chains ap-
peared within 4 min, and fully extended Ub chains formed after
another 4 min (Figure 7G), supporting a model of inefficient chain
initiation in trans followed by efficient chain extension in cis.
DISCUSSION
Here we propose a mechanism by which TRIM5 uses capsid
binding and autoubiquitination to translate virus recognition
into inflammatory signaling. TRIM5 forms a lattice of hexagonal
geometry that localizes RING domains into dynamic ‘‘two-
plus-one’’ constellations. Our data suggest that, rather than
the monomeric RING acting as a target-only ‘‘orphan’’ during
ubiquitination, the unique trimeric RING arrangement is a spe-
cific catalytic requirement wherein all three modules are active
and undergo partner exchange in order to extend N-K63-Ub
chains on TRIM5 (Figure 7H). TRIM5 RING dimers are energeti-
cally weak (Figure S1A), supporting such a model.
We identify the N terminus as the authentic site of TRIM5 au-
toubiquitination in cells. Previously, we were unable to identify
this site, because the TRIM5 extracted from cells under non-
denaturing conditions was acetylated at its N terminus (Fletcher
et al., 2015). Under non-denaturing conditions, all spatiotem-
poral cellular regulation is disrupted, meaning that non-physio-
logical enzymatic reactions can take place. In the present study,
we used denaturing conditions to preserve protein chemistries
that are present before the cells are lysed and processed. Using
these more stringent conditions, we find evidence for non-
acetylated TRIM5 N termini by mass spectrometry. We
employ N-monoUb-specific antiserum to confirm 2W-depen-
dent N-monoUb on TRIM5 in cells (Figure 4) and demonstrateoblot detecting TRIM5 and b-actin.
NG arrangement.
tecting FLAG tag, TRIM5 or Ub.
tecting TRIM5 or Ub.
d via addition of 2–3 Ub molecules to an N-monoUb, by 2N/V2 bound to an
can proceed across the RING dimer.
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ates K63-Ub anchoring to TRIM5 (Figure 5). As our mass spec-
trometry was not quantitative, it is possible that subpopulations
of TRIM5 exist, each bearing distinct N-terminal chemistries in a
location-, time-, or stimulation-dependent fashion. Nonetheless,
the distinctive site of TRIM5 autoubiquitination led us to explore
a role for the UFD pathway in TRIM5 function. In cells where
TRIM5 is functionally and stably expressed, Ub fusion drives
non-productive TRIM5 turnover before higher-order structures
accumulate. This is important as only during higher-order as-
sembly (e.g., during virus recognition) does TRIM5 convert
monoubiquitination from an innocuous degradation tag into an
inflammatory and proteasome recruitment signal.
The evolution of N-terminal ubiquitination and a two-plus-one
mechanism is likely a consequence of TRIM5’s functional and
regulatory requirements. TRIM5 must respond rapidly to
incoming virus and is only effective within a very limited time win-
dow, before the viral capsid has accessed the nuclear pore.
Consequently, TRIM5 is poised to assemble around the viral
capsid and has evolved an intrinsic tendency toward self-asso-
ciation. While advantageous for viral restriction, which only re-
quires caging of the virus and not ubiquitination (Figure 1), this
risks triggering innate immune activation in the absence of infec-
tion (Figure 3). We propose that, by marking itself with an
N-monoUb tag early during assembly, TRIM5 gains access to
the UFD machinery, constitutive turnover, and negative regula-
tion in the absence of infection (Figure S6D). Importantly, an
N-monoUb tag ensures that TRIM5 levels do not breach a
signaling threshold, either during constitutive expression or dur-
ing interferon stimulation, yet are sufficient to intercept an
incoming virus. Another advantage of N-terminal ubiquitination
could be that, being largely protein sequence independent, it al-
lows unconstrained TRIM5 evolution in pursuit of highly variable
retroviral capsids.
We demonstrate that TRIM5 autoubiquitination is the signal for
its own degradation by proteasomes. Such a mechanism ex-
plains why RING mutants that impair TRIM5 ubiquitination also
abolish TRIM5 turnover and restriction of vDNA synthesis. This
result also explains the observation that ectopic expression of
K63R Ub in cells specifically impaired restriction of vDNA syn-
thesis but not restriction of infection (Fletcher et al., 2015).
How N-K63-Ub leads to proteasome recruitment and immune
signaling in cells remains to be seen. Notably, proteins with
disordered N termini accumulate in testes of 2W knockout
mice (Wang et al., 2016), supporting a pivotal role for N-monoUb
in proteasome targeting. One possibility is that secondary Ub
linkages promote proteasome recruitment. Because TRIM5
and the UFD machinery both branch Ub chains from N-monoUb
(Figures 4 and 5) (Johnson et al., 1995), it is possible that the
UFD also recruits proteasomes to the assembled N-K63-Ub-
TRIM5-virus complex. Alternatively, Ub chain branching from
the N-K63-Ub scaffold could facilitate proteasome recruitment
(Ohtake et al., 2018), because K63R Ub expression also abol-
ished all TRIM5 polyUb labeling (Fletcher et al., 2015). Consistent
with this hypothesis, branched K48-K63 Ub chains exhibit the
combined phenotype of each individual linkage (Nakasone
et al., 2013) and underlie NF-kB activation by the TRIM-related
RING Ub ligase TRAF6 (Ohtake et al., 2016). Synchronization
of proteasome recruitment with innate immune signaling is sug-gested by the observations that incoming virus enhances both
TRIM5 turnover (Rold and Aiken, 2008) and immune signaling
(Figure 3) (Pertel et al., 2011).
Higher-order assembly is a central theme in innate immunity,
whereby transient signal activation occurs via colocalization of
weakly interacting intermediates, exemplified by inflamma-
somes and the CARMA1-BCL10-MALT1-TRAF6 signalosome
(David et al., 2018; Hauenstein et al., 2015). During infection,
TRIM5 uses higher-order assembly to promote capsid binding
through avidity. Our identification of CBs as signaling hubs sug-
gests that the TRIM5 lattice is in fact a pathogen-templated
signaling platform. A remarkable regulatory feature of this sys-
tem is that it is intrinsically self-limiting, because the same Ub
signal that stimulates immune signaling drives CB turnover. A
correlation between CB assembly and immunostimulation was
also observed in specific murine TRIM5 homologues (Lascano
et al., 2015), suggesting that this might be a unifying feature of
TRIM5-like proteins and perhaps of other immune TRIMs too.
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Antibodies
Mouse monoclonal anti-TRIM5 (5D5-1-1) Aids Reagents Cat#12272
Mouse monoclonal anti-b-actin-HRP (C4) Santa Cruz Cat#sc-47778 HRP, RRID: AB_2714189
Rat monoclonal anti-HA-HRP (3F10) Sigma-Aldrich Cat#12013819001, RRID: AB_390917
Rabbit polyclonal anti-HA Abcam Cat#ab9110, RRID: AB_307019
Mouse monoclonal anti-HA (16B12) BioLegend Cat#901501, RRID: AB_2565006
Mouse monoclonal anti-Ub-HRP (P4D1) Santa Cruz Cat#sc-8017, RRID: AB_628423
Mouse monoclonal anti-IkBa (L35A5) Cell Signaling Technology Cat#4814, RRID: AB_390781
Mouse monoclonal anti-phospho-IkBa (Ser32/36) Cell Signaling Technology Cat#9246, RRID: AB_2267145
Mouse monoclonal anti-NF-kB p65 (F-6) Santa Cruz Cat#sc-8008, RRID: AB_628017
Mouse polyclonal anti-N-monoUb This paper N/A
Mouse polyclonal anti-TRIM21 RING-B-Box2 This paper N/A
Rabbit polyclonal anti-GFP Abcam Cat#ab6556, RRID: AB_305564
Rabbit polyclonal anti-Ube2N BioRad Cat#AHP974, RRID: AB_567248
Donkey anti-Mouse IgG Alexa Fluor 488 Life Technologies Cat#A21202, RRID: AB_141607
Donkey anti-Rabbit IgG Alexa Fluor 568 Life Technologies Cat#A10042, RRID: AB_2534017
Rabbit monoclonal anti-PSMD14 (EPR4258) Abcam Cat#ab109130, RRID: AB_10861705
Mouse monoclonal anti-20Sa 1+2+3+5+6+7 (MCP231) Abcam Cat#ab22674, RRID: AB_2171376
Rabbit monoclonal anti-UCH37 (EP4897) Abcam Cat#ab133508
Rabbit monoclonal anti-USP14 (EPR15943) Abcam Cat#ab192618
Rabbit monoclonal anti-ADRM1 (EPR11450(B)) Abcam Cat#157218
Goat anti-Mouse IgG (Fc specific)-Peroxidase Sigma-Aldrich Cat#A0168, RRID: AB_257867
Goat anti-Rabbit IgG, HRP-linked Cell Signaling Technology Cat#7074, RRID: AB_2099233
Normal mouse polyclonal IgG control Merck Millipore Cat#12-371, RRID: AB_145840
Bacterial and Virus Strains
E. coli DH10B chemically competent Thermo Fisher Cat#18297010
E. coli C41 chemically competent John Walker N/A
Chemicals, Peptides, and Recombinant Proteins
Polybrene Santa-Cruz Cat#sc-134220
MG132 Calbiochem Cat#474790
Cycloheximide Calbiochem Cat#508739
Human TNFa PeproTech Cat#300-01A
Protein G Sepharose Generon Cat#PC-G5
Glutathione Sepharose 4B GE Healthcare Cat#17-0756-01
RING-B-Box2 (residues 1-132) This paper N/A
RING(E11R)-B-Box2 This paper N/A
RING(L19R)-B-Box2 This paper N/A
RING(V57R)-B-Box2 This paper N/A
RING(N70A)-B-Box2 This paper N/A
RING(V73A)-B-Box2 This paper N/A
RING(I76R)-B-Box2 This paper N/A
RING (residues 1- 87) This paper N/A
RING-GS-RING This paper N/A
UbRING-B-Box2 This paper N/A
Ub(G75/76A)RING-B-Box2 This paper N/A
(Continued on next page)
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Ub(G75/76A)RING(E11R)-B-Box2 This paper N/A
Ub(K63R,G75/76A)RING-B-Box2 This paper N/A
Ub(I44A,A46E,G47E,G75/76A)RING-B-Box2 This paper N/A
Ub(G75/76A)RING-GS-RING-Flag This paper N/A
Ub(G75/76A)RING(E11R)-GS-RING(E11R)-Flag This paper N/A
Ub(G75/76A)RING-GS-RING This paper N/A
Ub(G75/76A)RING-GS-RING(E11R) This paper N/A
Ub(G75/76A)RING(E11R)-GS-RING This paper N/A
RING-B-Box2 (residues 1-132) This paper N/A
UbeI This paper N/A
Ube2W (Fletcher et al., 2015) N/A
Ube2N (Fletcher et al., 2015) N/A
Ube2N(K92R) This paper N/A
Ube2V2 This paper N/A
Ubiquitin This paper N/A
Human 20S Proteasome BostonBiochem Cat#E-360; Lot#21118515D
Human 19S Proteasome BostonBiochem Cat#E-366; Lot#26730315A
Critical Commercial Assays
Dual Luciferase Reporter Assay System Promega Cat#E1910
RNeasy mini kit Qiagen Cat#74104
Gibson Assembly Master Mix New England BioLabs Cat#E2611
Experimental Models: Cell Lines
Human: Embryonic kidney 293T cells ATCC Cat#CRL-3216
Human: Rhabdomyosarcoma TE671 cells ATCC Cat#HTB-139
Human: Peripheral blood monocytic THP-1 cells ATCC Cat#TIB-202
Feline: Kidney epithelial CrFK cells ATCC Cat#CCL-94
Oligonucleotides
shRNA targeting sequence: TRIM5: CAGCCTTTCTATATCATCG (Stremlau et al., 2004) N/A
shRNA targeting sequence: Ube2W: GCATGATAGGGCCTATGAA (Fletcher et al., 2015) N/A
shRNA scrambled sequence: GTTATAGGCTCGCAAAAGG (Fletcher et al., 2015) N/A
sgRNA targeting TRIM5: CCTCCTCCTTTACATTAACC This paper sgRNA ‘D’
TaqMan GFP 5’-3’ primer: CAACAGCCACAACGTCTATATCAT (Fletcher et al., 2015) N/A
TaqMan GFP 3’-5’ primer: ATGTTGTGGCGGATCTTGAAG (Fletcher et al., 2015) N/A
TaqMan Probe: 5’[6FAM]CCGACAAGCAGAAGAACGGCATC
AA[TAM]3’
(Fletcher et al., 2015) N/A
Recombinant DNA
pCIG3-N This group N/A
pCIG3-B This group N/A
pCMV-Neo-CMV-GFP (CNCG) Yasu Takeuchi N/A
CSGW (cPPT-SFFV-GFP-WPRE) Adrian Thrasher N/A
CMVintron (CMVi) (Mo-MLV Gag-Pol) Francoise Loic Cosset N/A
p8.91Ex (HIV-1 Gag-Pol) Yasu Ikeda N/A
pMD2.G (VSV-G envelope) GenScript N/A
CMV-Ampho This group N/A
pONY3.1 (EIAV Gag-Pol) Kyriacos Mitrophanous N/A
pONY8.0 Kyriacos Mitrophanous N/A
SIREN-RetroQ Clontech N/A
HIV-SIREN This group N/A
pcDNA3.1(+) Life Technologies N/A
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EXNDHA EXN, Paul Bieniasz N/A
pIKK2Flag Felix Randow N/A
pGL4.32[luc2P/NF-kB-RE/Hygro] Promega Cat#9PIE849
pRL-TK Promega Cat#E2241
pLentiCRISPRv2 Brett Stringer Cat#98290
pQCXIP-Rpn11-HTBH Lan Huang N/A
TRIM and GFP Expression Constructs for Mammalian Cells,
see Table S1
This paper N/A
TRIM Expression Constructs for Bacterial Cells, see Table S2 This paper N/A
Software and Algorithms
DNADynamo v1.411 Blue Tractor Software N/A
Prism 7 GraphPad Software N/A
FlowJo FlowJo, LLC N/A
Scaffold4 (LC-MS/MS) Proteome Software N/A
ASTRA (SEC-MALLS) Wyatt Technology Corp N/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Leo
James (lcj@mrc-lmb.cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Cell lines were maintained at 37C in 5 % CO2 humidified incubators. Culture medium was DMEM (TE671 (Human, Female),
CrFK (Cat, Female) and 293T (Human Fetal)) or RPMI (THP-1 (Human, Male)), each supplemented with 9% (v/v) fetal calf serum,
100 U/mL penicillin, 100 mg/mL streptomycin. Cells were confirmed negative for mycobacteria contamination using the MycoAlert
Mycoplasma Detection Kit (Lonza). The identities of these cells lines were not authenticated during the course of this study.
Animal Husbandry
C57BL/6 wild-type mice were obtained from Jackson Laboratories. Mice were bred and housed under specific pathogen-free con-
ditions in the Animal Research facilities at the Babraham campus, Cambridge, UK. Thirteen week old-mice of both genders were
used for the immunisation experiment, which was conducted in accordance with the 19.b.5 moderate severity limit protocol and
Home Office Animals (Scientific Procedures) Act (1986). All animal work was licensed under the UK Animals (Scientific Procedures)
Act, 1986 and approved by theMedical Research Council AnimalWelfare and Ethical ReviewBody. Throughout the protocol, animals
were weighed and observed twice daily for clinical signs of infection, which included subdued behaviour, pilo-erection, hunched
posture, ataxia, and paresis. Animals that reached the end of the experiment, lost more than 20% of initial body weight, or showed
clinical signs that failed to improve over a 6 hr period were killed. Serum was prepared from intracardiac blood and frozen in liquid
nitrogen.
Bacteria
E. coli strain C41 was used to produce recombinant protein for biochemical characterisation experiments. C41 cells were trans-
formed and grown at 37C to derive single-cell colonies. Colonies were picked and grown in liquid 2xTY media overnight at 37C,
and then grown at 34C until induction at an optical density at 600 nm of 0.8, then grown overnight at 16C in the presence of
1 mM IPTG.
METHOD DETAILS
Virus Restriction Assays
CrFK or TE671 cells were infected with DNase-treated N-MLV- or B-MLV-GFP viral vector supernatants in the presence of 8 mg/mL
polybrene. 6 hr post infection (p.i.), duplicate wells were pelleted and stored at -80C. 48 hr p.i., duplicate wells were scored for GFP
expression by flow cytometry (FACSCalibur). Total DNAwas extracted from 6 hr samples using QIAampDNAMini Kit (Qiagen). Heat-
treated viral supernatants (95C, 5 min) served as controls for plasmid contamination. Concentration of each DNA sample wase3 Cell Host & Microbe 24, 1–15.e1–e6, December 12, 2018
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eluted DNA, 300 nM forward and reverse primers against GFP, 150 nMprobe, 20 mg salmon spermDNA, and TaqMan Fast Advanced
Master Mix (ThermoFisher Scientific). Standard curves generated from GFP cDNA plasmids were created for each assay. Cycle pa-
rameters for gene detection were 95C for 20 sec, then 40 cycles of 95C for 1 sec, 60C for 20 sec, using a StepOnePlus thermo-
cycler (Applied Biosystems).
Viral Vectors, Mutant cDNAs
As described (Fletcher et al., 2015), VSV-G pseudotyped viral particles were generated by three-plasmid transfection of 293T with
Fugene-6 (Promega), using 1 mg Gag-Pol expression plasmid, 1 mg VSV-G expression plasmid pMD2.G (GenScript) or CMV-Ampho,
and 1.5 mg genome vector encoding cDNAs or shRNAs. TRIM5 mutants were generated by site-directed mutagenesis using
PfuTurbo (Agilent Technologies).
Cloning
Site-directed mutagenesis was performed using Pfu Turbo. Synthesis of fused RING-RING constructs was carried out using Gibson
cloning and Gibson Assembly Master Mix (New England BioLabs) following manufacturer’s instructions.
Protein Depletion
Short-hairpin RNA (shRNA): Cells depleted of 2W or TRIM5 were prepared as described (Fletcher et al., 2015). Briefly, pSIREN-
RetroQ or HIV-SIREN expressing shRNA against 2W or TRIM5, respectively, were transfected into 293T cells and MLV or HIV-1 viral
vectors prepared as described. Cells were transduced at an MOI  1 and shRNA-expressing cells selected with 2.5 – 10 mg/mL pu-
romycin. 2W expression was quantified by qPCR relative to ACTB using TaqMan Gene Expression Assays for 2W (Hs00217672_m1)
and ACTB (Hs01060665_g1), by the DDCt method.
CRISPR/Cas9: TE671 stably depleted of TRIM5 were generated by transduction with HIV-1-based lentivectors carrying Cas9-2A-
Puromcin and single guide RNA (sgRNA) expression cassettes (pLentiCRISPRv2 Puro, a gift from Brett Stringer (Addgene plasmid #
98290). DNA oligonucleotides for generation of sgRNA were synthesised (Sigma Aldrich), annealed, and cloned into the linearized
vectors. Cells were selected with Puromycin. To reconstitute these cells, TRIM5 was silently mutated at the PAM site before reintro-
duction by transduction with MLV vectors.
Reconstitution of TRIM5 in TRIM5 depleted cells: TRIM5 was silently mutated using forward primer (CTGGAATTTTGGTTAATG
TAAAGGAGGAGG) and reverse primer (CATTAACCAAAATTCCAGAAGCCATGGTGG) to remove the PAM site for TRIM5-specific
sgRNA (CCTCCTCCTTTACATTAACC). Mutant TRIM5 cDNAs were packaged in MLV viral vectors and TRIM5 depleted cells were
transduced as described above.
Cycloheximide Chase and Immunoblotting
Cells expressing HA-tagged TRIM5a proteins were treated with 100 mg/mL cycloheximide for up to 6 hr, washed, lysed in 2X LDS
Loading Buffer (Life Technologies) with 50 mM DTT, heated at 95C for 5 min, then resolved by SDS-PAGE using NuPAGE
4-12 % Bis-Tris Protein Gels (Life Technologies). Proteins were transferred to nitrocellulose membranes using the iBlot Gel Transfer
Device (Life Technologies). Membranes were incubated in blocking buffer (phosphate buffered saline (PBS)/0.1% Tween-20 (PBST)
containing 5 % milk), incubated in blocking buffer containing primary and secondary antibodies, 33 5 min PBST washes after each
antibody. HRP-conjugated antibodies were detected using Amersham ECL Western Blotting Detecting Reagent (GE Healthcare).
Innate Immune Stimulation Experiments
In response to virus: THP-1 cells were seeded in 24 or 96 well plates and differentiated with 100 ng/mL 12-O-Tetradecanoylphorbol-
13-acetate (TPA, Sigma-Aldrich) for 24 hr, washed, incubated at 37C for 48 hr. Then, cells were infected with N- and B-MLV pseu-
dotyped with an MLV-amphoteric envelope glycoprotein, at MOI10, in the presence of 8 mg/mL polybrene (Santa Cruz). Cells were
washed and frozen at -20C at 1.5-2 hr post infection. Total RNA was extracted (Qiagen RNeasy kit) and reverse transcription per-
formed using SuperScript II (Thermo Fisher Scientific). qPCR reactions were performed with TaqMan Gene Expression Assays
(Thermo Fisher Scientific) for, ACTB (Hs01060665_g1), IL6 (Hs00174131_m1), IL1B (Hs00174097_m1), IFNB1 (Hs01077958_s1),
TNFA (Hs00174128_m1), IFIT1 (Hs00356631_g1), NLRP3 (Hs00366461_m1), PTGS2 (Hs00153133_m1), SOD2 (Hs00167309_m1),
and TaqMan Fast AdvancedMaster Mix (Thermo Fisher Scientific). Cycle parameters for gene detection were as for detection of viral
DNA above. Fold changes in mRNA were caluculated by the DDCt method using ACTB as the uninduced control.
In response to TRIM overexpression: 293T cells were seeded in 24 well plates 24 hr before transfection. Each well was transfected
with 0.3–100 ng pcDNA or EXN derived vectors containing the relevant TRIM cDNA, with 10 ng pGL4.32[luc2P/NF-kB-RE/Hygro]
(NF-kB response element-dependent firefly luciferase, FLuc) and 5 ng pRL-TK (thymidine kinase promoter-dependent Renilla lucif-
erase, RLuc). 24 hr post transfection, cells were lysed in Passive Lysis Buffer and sequential firefly and renilla luminesence measured
(BMG Pherastar plate reader), according to manufacturers instructions (Promega). FLuc:RLuc ratios of each construct were
normalised to those of empty vector alone.Cell Host & Microbe 24, 1–15.e1–e6, December 12, 2018 e4
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Wild-type and N-terminal monoubiquitinated TRIM5RING, RING-RING andRING-B-Box2 proteins, and E1, Ube2N, Ube2V2 and 2W
were expressed in C41 cells as GST-TEV-fusion proteins. Cleared cell lysates were prepared by sonication in 50 mM Tris, pH 8.0,
150 mM NaCl, 2 mM DTT, 2 mM ZnCl2, 1 mg/mL lysozyme, 0.1 mg/mL DNaseI with the addition of cOmplete, EDTA-free Protease
Inhibitor Cocktail (Roche), followed by centrifugation at 19,0003 g for 1 hr at 4C. Lysates were loaded onto equilibrated glutathione
sepharose resin andwashed with three column volumes of lysis buffer, then cleaved with recombinant His-TEV protease overnight at
4C. Cleaved proteins were concentrated, His-TEV was removed on Ni2+-NTA agarose, and TRIM5 or E2 proteins resolved by size-
exclusion chromatography (HiLoad 26/60 Superdex 75 size exclusion column, GE Healthcare). Peak fractions were pooled, concen-
trated, and frozen in aliquots at -80C. TEV cleavage leaves a GSH tripeptide at the N terminus of TRIM5 proteins. To prevent
cleavage of Ub from RB by bacteria and allowing purification to homogeneity (Ub(GA)RB) (Figure S4B), we changed N-terminal
Ub residues Gly75 and Gly76 to alanine.
Cellular Proteasome Purification
Cellular proteasomes were isolated using a protocol adopted from that described in Wang et al. (2007). pQCXIP-Poh1-His-TEV-
Biotin-His (HTBH) was transfected into 293T cells with CMVi and pMD2.G to generate MLV viral vectors. TE671 cells were trans-
duced with viral vectors and Poh1-HTBH was stably expressed by selection with 10 mg/mL puromycin selection. Confluent 10 cm
dishes were trypsinised, washed three times with PBS, and lysed in 100 mM NaCl, 50 mM Na2HPO4/NaH2PO4, 10 % glycerol,
5 mM ATP, 1 mM DTT, 5 mM MgCl2, 0.5 % NP-40, protease and phosphatase inhibitors, pH 7.5. Lysates were passed through a
25 G syringe four times then centrifuged 15,000 3g, 15 min, 4C. Insoluble material was discarded and cell lysates were incubated
with equilibrated glutathione sepharose resin overnight at 4C. Resin was washed twice with 203 bed volume of lysis buffer, 13with
50 mMTris pH 7.5, 10% glycerol, and incubated for 1 hr at 22C in the same buffer, 23 bed volume, with 30 mL recombinant His-TEV
protease. The presence of 20S and 19S components was confirmed by immunoblot (see Figure S5E).
Immunoprecipitations and His-Pulldowns
Immunoprecipitations: Cells were washed twice in ice-cold PBS and collected into ice-cold lysis buffer (10 mM Tris, pH 7.4,
200 mM NaCl, 3 mM MgCl2, 2 mM DTT, 0.5% Triton-X-100, cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche)), 1 mL per
10 cm dish. Cells were passed 5 3 through a 25 G needle, rotated at 4C for 20 min and centrifuged at 15,000 3g at 4C for
10 min. Cell lysates were transferred to fresh tubes and 30 mL kept for ‘input’ fractions. Anti-N-monoUb antibodies were first pre-ad-
sorbed on plates coatedwith recombinant RB protein, and added to lysates at a final concentration of 1:10,000. Lysates were rotated
overnight at 4C, then 50 mL 50% equilibrated protein G sepharose (Generon) was added per 1 mL lysate and rotated for 1–4 hr at
4C. Sepharose was centrifuged < 1000 3g for 30 sec at 4C and washed three times. Immunoprecipitants were snap frozen on
beads for LC-MS/MS analysis.
His-pulldown: As previously described (Fletcher et al., 2015). Cells were lysed in 6 M Guanidine hydrochloride pH 8, before
incubation with Nickel NTA overnight. Beads were washed and precipitants analysed by SDS-PAGE.
In Vitro Ub Assays
Elongation assays: In vitro ubiquitination reactions were carried out in 13 ubiquitination buffer (50 mM Tris pH 7.4, 2.5 mM MgCl2,
0.5 mM DTT) with the addition of 2 mM ATP, 0.5 mM Ube1, 0.7 mM 2W, 0.3–1 mM Ube2N/Ube2V2, 4 mg Ub and 1 mM E3. Reaction
mixtures were incubated at 37C for 1 hr, quenched by addition of LDS sample buffer and boiling at 95C for 5 min.
Deubiquitination/degradation reactions: 10 mL 26S proteasome preparations were added to elongation assays after 1 hr ubiquiti-
nation reactions. Reaction mixtures were incubated at 37C for 1 hr, quenched by addition of LDS sample buffer and boiling at 95C
for 5 min.
Single turnover E2Ub discharge assays: 40 mM Ube2N(K92R) was incubated for 30 min at 37C with 370 mM Ub, 1 mM Ube1,
3 mM ATP in discharge buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 20 mM MgCl2). Then, 2 mM Ube2N(K92R)Ub was mixed
2.5 mMUbe2V2 and 1.5 mM TRIM5 protein in discharge buffer, supplemented with 50 mM L-Lysine. Samples were taken at the indi-
cated time intervals, mixed with LDS sample buffer and boiled for 20 s, then resolved by LDS-PAGE and observed by immunoblot
using anti-Ube2N (BioRad, AHP974, 1:1,000)
Confocal Microscopy
TE671, CrFK and 293T cells were seeded on round coverslips, pre-coated with poly-D-lysine for 293T cells. Cells were fixed for
10 min in 4 % paraformaldehyde, permeabilised for 20 min with 0.1 % Triton-X 100 and blocked for 1 hr with 5 % BSA in phosphate
buffered saline (PBS). Intracellular targets were stained with specific antibodies for 1-2 hr at room temperature in 5 % BSA/PBS, fol-
lowed by incubation with Alexa Fluor conjugated secondary antibodies for 1-2 hr at room temperature in 5 % BSA/PBS in the dark.
Nuclei were detected with Hoesct 33342 (Life Technologies), and coverslips were mounted using SlowFade Diamond Antifade
Mountant (Life Technologies). Imaging acquisition was performed on a Zeiss 780 inverted microscope (Zeiss) using 403 or 633
Oil objectives, using the Zen 2011 software. Images were analysed using FIJI/ImageJ software. To quantify TRIM5 CB, CB-contain-
ing cells were counted in 8-10 fields of view, translated into percentage of cells counted, then multiplied by the total number of cells
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13weeks old C57BL/6mice (n = 10) were immunised subcutaneously (s.c) with 100 mgUb(GA)RB protein in PBSmixedwith complete
Freund’s adjuvant followed by 3 rounds of s.c boosting with 50 mg protein mixed with incomplete Freund’s adjuvant. Boosting was
done at days 24, 46 and 84. Tail bleeds for ELISA analyses were collected ad days 34, 59. Mice were sacrificed at day 105 and Intra-
cardiac blood was collected.
ELISA
96well plates (Nunc) were coated overnight with 1 mg/ml of Ub(GA)RING-B-Box2 (RB), RB or Ub. Plates were blockedwith 2%milk in
PBS, 0.05% Tween 20 (MPBST). Polyclonal sera diluted 1:60,000 inMPBSTwas pre-absorbed against a RB-coated plate for 35min.
Serumwas removed from the plates, further diluted to 1:300,000 with MPBST and incubated for 1 hr on fresh antigen-coated plates.
Plates were washed with PBST. Bound antibodies were detected with goat anti-mouse IgG-HRP (Jackson Immunoresearch, 115-
035-071).
SEC-MALLS
100 mL TRIM5 RING-B-Box2 and Ub(G75/76A)RING-B-Box2 proteins were injected at 10 mg/mL in and resolved on a GE Superdex
75 10/300 GL (GE Healthcare) analytical column equilibrated in 50 mM Tris, pH 8.0, 150 mMNaCl, 1 mMDTT, in line with multi-angle
laser light scattering using a Wyatt HELEOS-II 18-angle photometer coupled to a Wyatt Optilab rEX differential refractometer (Wyatt
Technology Corp). Molecular weight calibration was performed with Bovine serum albumin (BSA). Data were collected and analyzed
using ASTRA software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was determined by unpaired t tests, using Graphpad Prism 7 software. P values less than 0.05 were consid-
ered statistically significant. It was assumed that bothWT TRIM5 and Ub(GA)TRIM5 were equally visible to N-monoUb- and K63-Ub-
specific antibodies in untreated cells, which we also demonstrated. Where unstated, n = number of experimental replicates
represented by data shown.Cell Host & Microbe 24, 1–15.e1–e6, December 12, 2018 e6
